Reduces symptoms of intermittent claudication. ANDA 77030, held by Apotex. Cilostazol.
As of Nov 16, 2026, ANDA 77030 (Cilostazol), held by Apotex, was first approved by FDA on Dec 10, 2004, with 5 approved supplements and 0 published complete response letters.
Cilostazol tablets are indicated for the reduction of symptoms of intermittent claudication, as demonstrated by an increased walking distance.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 10, 2004 | Original application | Approved | None posted |
| Cilostazol50MG · tablet;oral | Cilostazol | Rx |
| Cilostazol100MG · tablet;oral | Cilostazol | Rx |
| Nov 16, 2020 | Supplement 7Labeling · Standard review | Approved | None posted |
| Apr 4, 2016 | Supplement 5Labeling · Standard review | Approved | None posted |
| Apr 4, 2016 | Supplement 6Labeling · Standard review | Approved | None posted |
| Aug 29, 2008 | Supplement 2Labeling | Approved | None posted |
| Aug 16, 2007 | Supplement 1Labeling | Approved | None posted |
| Dec 10, 2004 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters